Canadian clinical practice guidelines for invasive candidiasis in adults.
暂无分享,去创建一个
D. Vinh | R. Rennie | E. Bow | S. Shafran | G. Evans | M. Laverdière | J. Fuller | C. Rotstein | P. Phillips | D. Sheppard | Sylvie Carle | G. Evans
[1] C. Bassi,et al. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. , 2010, The Cochrane database of systematic reviews.
[2] T. Barbui,et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] T. Walsh,et al. Candida bloodstream infections in hemodialysis recipients. , 2009, Medical mycology.
[4] B. Allegranzi,et al. The World Health Organization Guidelines on Hand Hygiene in Health Care and Their Consensus Recommendations , 2009, Infection Control & Hospital Epidemiology.
[5] P. Charles,et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study , 2009, Critical care medicine.
[6] A. Vekhoff,et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] P. Martín-Dávila,et al. Prophylaxis With Caspofungin for Invasive Fungal Infections in High-Risk Liver Transplant Recipients , 2009, Transplantation.
[9] C. Junghanss,et al. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) , 2009, Annals of Hematology.
[10] Marianne Opilla. Epidemiology of bloodstream infection associated with parenteral nutrition. , 2008, American journal of infection control.
[11] L. Leibovici,et al. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. , 2008, European journal of cancer.
[12] L. Leibovici,et al. Treatment of invasive candidal infections: systematic review and meta-analysis. , 2008, Mayo Clinic proceedings.
[13] D. Sheppard,et al. Utility of the Germ Tube Test for Direct Identification of Candida albicans from Positive Blood Culture Bottles , 2008, Journal of Clinical Microbiology.
[14] T. Patterson,et al. Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection , 2008, Antimicrobial Agents and Chemotherapy.
[15] M. Ghannoum,et al. Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints , 2008, Journal of Clinical Microbiology.
[16] D. Kontoyiannis,et al. The changing epidemiology of invasive candidiasis , 2008, Cancer.
[17] O. Cornely,et al. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] G. Garber,et al. Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[19] T. Calandra,et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] R. Hay,et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] P. Rohrlich,et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] E. Bow. Considerations in the approach to invasive fungal infection in patients with haematological malignancies , 2007, British journal of haematology.
[23] L. Leibovici,et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Dipersio,et al. Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients. , 2007 .
[25] R. Drew,et al. Antifungal serum concentration monitoring: an update. , 2007, The Journal of antimicrobial chemotherapy.
[26] G. Wassmer,et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). , 2007, The Journal of infection.
[27] R. Betts,et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] C. Lass‐Flörl,et al. Primary antifungal prophylaxis in leukaemia patients , 2007 .
[29] A. Thiébaut,et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients , 2007 .
[30] T. Calandra,et al. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever , 2007 .
[31] R. Betts,et al. Anidulafungin versus fluconazole for invasive candidiasis. , 2007, The New England journal of medicine.
[32] S. Husain,et al. Fungal infections in solid organ transplantation. , 2007, Medical mycology.
[33] G. Fadda,et al. Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia , 2007, Journal of Clinical Microbiology.
[34] J. Meis,et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing , 2007, Journal of Clinical Microbiology.
[35] K. Garey,et al. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis , 2007, Current medical research and opinion.
[36] J. Maertens. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies , 2007, European journal of haematology.
[37] B. Alexander,et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[38] J. Lipton,et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.
[39] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[40] D. Spelman,et al. Rapid differentiation of Candida albicans from non‐albicans species by germ tube test directly from BacTAlert blood culture bottles , 2007, Mycoses.
[41] M. Pfaller,et al. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.
[42] J. Sobel. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia , 2006, Current infectious disease reports.
[43] D. Marriott,et al. Active Surveillance of Candidemia, Australia , 2006, Emerging infectious diseases.
[44] P. Lipsett. Surgical critical care: Fungal infections in surgical patients , 2006, Critical care medicine.
[45] M. Kollef. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] A. Webster,et al. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients , 2006, European Journal of Clinical Microbiology and Infectious Diseases.
[47] G. Mayer,et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants , 2006, BMC infectious diseases.
[48] Peter G. Pappas,et al. Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .
[49] D. Andes,et al. Pharmacology of Systemic Antifungal Agents , 2006 .
[50] Benjamin J Park,et al. Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers , 2006, Journal of Clinical Microbiology.
[51] D. Pittet,et al. Treatment options of invasive fungal infections in adults. , 2006, Swiss medical weekly.
[52] K. Garey,et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] J. Staab,et al. Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy , 2006, Antimicrobial Agents and Chemotherapy.
[54] G. Lyon,et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] S. Gruber,et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors , 2006, Clinical transplantation.
[56] Robert B Sim,et al. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. , 2006, The Journal of infectious diseases.
[57] L. Bevanger,et al. Candidemia in Norway (1991 to 2003): Results from a Nationwide Study , 2006, Journal of Clinical Microbiology.
[58] Sergey V. Balashov,et al. Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.
[59] K. Wood,et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.
[60] A. Muriel,et al. Risk Factors for Candidemia in Pediatric Patients With Congenital Heart Disease , 2006, Infection Control & Hospital Epidemiology.
[61] P. Grossi,et al. Antifungal prophylaxis in liver transplant patients: A systematic review and meta‐analysis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[62] R. Grillot,et al. Candidaemia in Europe: epidemiology and resistance. , 2006, International journal of antimicrobial agents.
[63] Russell E. Lewis,et al. Evaluation of antifungals in the surgical intensive care unit: a multi‐institutional study , 2006, Mycoses.
[64] Siamon Gordon,et al. The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. , 2006, Glycobiology.
[65] Kieren A. Marr,et al. Clinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrata , 2006, Journal of Clinical Microbiology.
[66] Ronald N. Jones,et al. International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003) , 2006, Journal of Clinical Microbiology.
[67] S. Fridkin,et al. Evaluation of Amphotericin B Interpretive Breakpoints for Candida Bloodstream Isolates by Correlation with Therapeutic Outcome , 2006, Antimicrobial Agents and Chemotherapy.
[68] W. Ko,et al. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. , 2006, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[69] M. Arendrup,et al. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[70] M. Pfaller,et al. Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing , 2006, Clinical Microbiology Reviews.
[71] D. Perlin,et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. , 2006, The Journal of antimicrobial chemotherapy.
[72] A. Webster,et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. , 2006, The Journal of antimicrobial chemotherapy.
[73] H. Endtz,et al. Candida krusei Transmission among Hematology Patients Resolved by Adapted Antifungal Prophylaxis and Infection Control Measures , 2006, Journal of Clinical Microbiology.
[74] M. Pfaller,et al. In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance , 2006, Journal of Clinical Microbiology.
[75] Benjamin J Park,et al. Candidemia in Neonatal Intensive Care Units: Barcelona, Spain , 2006, The Pediatric infectious disease journal.
[76] M. Ghannoum,et al. Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints , 2006, Journal of Clinical Microbiology.
[77] J. Garnacho-Montero,et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization* , 2006, Critical care medicine.
[78] Masahiro Yoshida,et al. surgical management , 2022 .
[79] M. Choti,et al. Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy , 2006, Journal of Clinical Microbiology.
[80] A. Webster,et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. , 2016, The Cochrane database of systematic reviews.
[81] P. Gøtzsche,et al. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations , 2006, Trials.
[82] S. Filler,et al. Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] R. Betts,et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients , 2006, Cancer.
[84] E. Estey,et al. Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.
[85] John B Wong,et al. Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis , 2005, Annals of Internal Medicine.
[86] P. Hsueh,et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. , 2005, International journal of antimicrobial agents.
[87] J. Berlin,et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[88] S. Fridkin. Candidemia is costly--plain and simple. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] G. Verhoef,et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] A. Zaas,et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. , 2005, The Journal of infection.
[91] M. Falagas,et al. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials , 2005, British journal of haematology.
[92] Jong-Hee Shin,et al. PFGE-based epidemiological study of an outbreak of Candida tropicalis candiduria: the importance of medical waste as a reservoir of nosocomial infection. , 2005, Japanese journal of infectious diseases.
[93] J. Perfect,et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. , 2005, Transplantation.
[94] L. Baden. Prophylactic antimicrobial agents and the importance of fitness. , 2005, The New England journal of medicine.
[95] M. Motyl,et al. Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome , 2005, Antimicrobial Agents and Chemotherapy.
[96] H. Schønheyder,et al. Seminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility , 2005, Journal of Clinical Microbiology.
[97] D. Church,et al. Invasive Candida species infections: a 5 year population-based assessment. , 2005, The Journal of antimicrobial chemotherapy.
[98] Victoria J. Fraser,et al. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.
[99] J. Warmington,et al. Syscan3, a Kit for Detection of Anti-Candida Antibodies for Diagnosis of Invasive Candidiasis , 2005, Journal of Clinical Microbiology.
[100] A. Glasmacher,et al. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. , 2005, The Journal of antimicrobial chemotherapy.
[101] J. R. Contreras,et al. RESPIRATORY SYNCYTIAL VIRUS AND HUMAN METAPNEUMOVIRUS IN CHILDREN WITH ACUTE RESPIRATORY INFECTIONS IN YEMEN , 2005, The Pediatric infectious disease journal.
[102] M. Pfaller,et al. In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods , 2005, Journal of Clinical Microbiology.
[103] S. Fridkin,et al. Determining Risk Factors for Candidemia Among Newborn Infants From Population-Based Surveillance: Baltimore, Maryland, 1998–2000 , 2005, The Pediatric infectious disease journal.
[104] V. Abraira,et al. Secular Trends of Candidemia in a Large Tertiary-Care Hospital From 1988 to 2000: Emergence of Candida parapsilosis , 2005, Infection Control & Hospital Epidemiology.
[105] S. Teutsch,et al. Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia Surveillance , 2005, Infection Control & Hospital Epidemiology.
[106] J. Rex,et al. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. , 2005, Medical mycology.
[107] S. Sallah,et al. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. , 2005, Leukemia research.
[108] F. Persat,et al. Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001 , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[109] J. Sim,et al. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. , 2005, Hong Kong medical journal = Xianggang yi xue za zhi.
[110] S. Fridkin,et al. Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 , 2005, Journal of Clinical Microbiology.
[111] N. Prasadarao,et al. N-cadherin Mediates Endocytosis of Candida albicans by Endothelial Cells* , 2005, Journal of Biological Chemistry.
[112] Yun-Liang Yang,et al. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. , 2005, Diagnostic microbiology and infectious disease.
[113] Deborah J Cook,et al. Management of the critically ill patient with severe acute pancreatitis , 2004, Critical care medicine.
[114] J. Quenot,et al. Candida spp. colonization significance in critically ill medical patients: a prospective study , 2005, Intensive Care Medicine.
[115] M. Cuenca‐Estrella,et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. , 2005, The Journal of antimicrobial chemotherapy.
[116] R. Piarroux,et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients(*) , 2004, Critical care medicine.
[117] L. Ostrosky-Zeichner. Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? , 2004, Critical care medicine.
[118] A. Milstone,et al. A survey of anti-fungal management in lung transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[119] J. Lipton,et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[120] M. Pfaller,et al. Evaluation of the Etest Method Using Mueller-Hinton Agar with Glucose and Methylene Blue for Determining Amphotericin B MICs for 4,936 Clinical Isolates of Candida Species , 2004, Journal of Clinical Microbiology.
[121] R. Orenstein,et al. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[122] Nina Singh,et al. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[123] S. Fridkin,et al. Epidemiologic and Molecular Characterization of an Outbreak of Candida parapsilosis Bloodstream Infections in a Community Hospital , 2004, Journal of Clinical Microbiology.
[124] J. Neoptolemos,et al. Fungal Infection but Not Type of Bacterial Infection Is Associated with a High Mortality in Primary and Secondary Infected Pancreatic Necrosis , 2004, Digestive Surgery.
[125] D. Church,et al. Intensive-care-unit-acquired bloodstream infections in a regional critically ill population. , 2004, The Journal of hospital infection.
[126] Thomas J Walsh,et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.
[127] R. Wenzel,et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[128] M. Pfaller,et al. Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure , 2004, Infection Control & Hospital Epidemiology.
[129] J. Perfect,et al. Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species , 2004, Journal of Clinical Microbiology.
[130] G. Fadda,et al. Candida parapsilosis Bloodstream Infection in Pediatric Oncology Patients: Results of an Epidemiologic Investigation , 2004, Infection Control & Hospital Epidemiology.
[131] M. Montagna,et al. Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit. , 2004, Diagnostic microbiology and infectious disease.
[132] R. Ohno,et al. Antimicrobial prophylaxis in febrile neutropenia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[133] S. Kalaça,et al. The relationships between candidemia and candidal colonization and virulence factors of the colonizing strains in preterm infants. , 2004, The Turkish journal of pediatrics.
[134] M. Pfaller,et al. Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates , 2004, Journal of Clinical Microbiology.
[135] W. Bilker,et al. Risk Factors for Disseminated Candidiasis in Children with Candidemia , 2004, The Pediatric infectious disease journal.
[136] M. Pfaller,et al. Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 , 2004, Journal of Clinical Microbiology.
[137] M. Kami,et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan , 2004, Bone Marrow Transplantation.
[138] S. Suh,et al. Molecular investigation of two consecutive nosocomial clusters of Candida tropicalis candiduria using pulsed-field gel electrophoresis. , 2004, Journal of microbiology.
[139] H. Ohge,et al. Combined Assessment of β-d-Glucan and Degree of Candida Colonization before Starting Empiric Therapy for Candidiasis in Surgical Patients , 2004, World Journal of Surgery.
[140] Lee H. Harrison,et al. Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.
[141] R. Darouiche,et al. Candida Infections of Medical Devices , 2004, Clinical Microbiology Reviews.
[142] J. Mehta,et al. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice , 2004, Bone Marrow Transplantation.
[143] Steve A. Hernandez,et al. Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis , 2004, Antimicrobial Agents and Chemotherapy.
[144] T. Sorrell,et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections , 2004, Internal medicine journal.
[145] O. Faure,et al. Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[146] M. Netea,et al. Toll-Like Receptor 2 Suppresses Immunity against Candida albicans through Induction of IL-10 and Regulatory T Cells , 2004, The Journal of Immunology.
[147] M. Pfaller,et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. , 2004, Diagnostic microbiology and infectious disease.
[148] W. Leisenring,et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.
[149] D. Pittet,et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[150] J. Sobel,et al. Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[151] T. Kozel,et al. Biological Activities of Naturally Occurring Antibodies Reactive with Candida albicans Mannan , 2004, Infection and Immunity.
[152] B. Djulbegovic,et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[153] Zhi-su Liu,et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. , 2003, World journal of gastroenterology.
[154] D. Pittet,et al. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. , 2003, The Lancet. Infectious diseases.
[155] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[156] W. Bechstein,et al. Value of donor swabs for intra-abdominal infection in simultaneous pancreas-kidney transplantation , 2003, Transplantation.
[157] D. Denning. Echinocandin antifungal drugs , 2003, The Lancet.
[158] A. Bonnin,et al. Contribution of the Platelia Candida-Specific Antibody and Antigen Tests to Early Diagnosis of Systemic Candida tropicalis Infection in Neutropenic Adults , 2003, Journal of Clinical Microbiology.
[159] D. Johnston,et al. Parenchymal Organ, and Not Splenic, Immunity Correlates with Host Survival during Disseminated Candidiasis , 2003, Infection and Immunity.
[160] J. Cleary,et al. Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States , 2003, Antimicrobial Agents and Chemotherapy.
[161] J. Quenot,et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients , 2003, Intensive Care Medicine.
[162] O. Sezer,et al. Antimicrobial therapy of unexplained fever in neutropenic patients , 2003, Annals of Hematology.
[163] W. Powderly,et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[164] A. Chowdhary,et al. An outbreak of candidemia due to Candida tropicalis in a neonatal intensive care unit , 2003, Mycoses.
[165] R. Wenzel,et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities , 2003, The Pediatric infectious disease journal.
[166] V. Anttila,et al. Candidemia in Finland, 1995–1999 , 2003, Emerging infectious diseases.
[167] Osamu Takeuchi,et al. Candida albicans phospholipomannan is sensed through toll-like receptors. , 2003, The Journal of infectious diseases.
[168] H. Ulmer,et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution , 2003, Annals of Hematology.
[169] W. Trick,et al. Impact of ring wearing on hand contamination and comparison of hand hygiene agents in a hospital. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[170] M. Büchler,et al. IAP Guidelines for the Surgical Management of Acute Pancreatitis , 2003, Pancreatology.
[171] M. Territo,et al. Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.
[172] M. Pfaller,et al. Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location , 2003, Journal of Clinical Microbiology.
[173] O. Cornely,et al. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. , 2003, Blood.
[174] D. Mannino,et al. The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.
[175] D. Denning,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Microbiology Standards of Care British Society for Medical Mycology Proposed Standards of Care for Patients with Invasive Fungal Infections , 2022 .
[176] R. Rennie,et al. Sublethal Injury and Resuscitation of Candida albicans after Amphotericin B Treatment , 2003, Antimicrobial Agents and Chemotherapy.
[177] C. Verhagen,et al. Can anything be done about oral mucositis? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[178] M. Pfaller,et al. Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 , 2003, Journal of Clinical Microbiology.
[179] Michael K Gould,et al. Preventing complications of central venous catheterization. , 2003, The New England journal of medicine.
[180] J. Mantz,et al. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?* , 2003, Critical care medicine.
[181] Alessandra Cambi,et al. The C‐type lectin DC‐SIGN (CD209) is an antigen‐uptake receptor for Candida albicans on dendritic cells , 2003, European journal of immunology.
[182] Julian de Meyrick,et al. The Delphi method and health research , 2003 .
[183] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[184] M. Nussenzweig,et al. Disseminated Candidiasis and Hepatic Malarial Infection in Mannose-Binding-Lectin-A-Deficient Mice , 2002, Molecular and Cellular Biology.
[185] M. Pfaller,et al. In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods , 2002, Antimicrobial Agents and Chemotherapy.
[186] D. Pittet,et al. Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital , 2002, Medicine.
[187] M. Pfaller,et al. Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.
[188] R. Rubin. Overview: pathogenesis of fungal infections in the organ transplant recipient. , 2002, Transplant infectious disease : an official journal of the Transplantation Society.
[189] L. R. Ásmundsdóttir,et al. Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland , 2002, Journal of Clinical Microbiology.
[190] R. Gaynes,et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[191] B. Kubak. Fungal infection in lung transplantation. , 2002, Transplant infectious disease : an official journal of the Transplantation Society.
[192] B. Alexander. Diagnosis of fungal infection: new technologies for the mycology laboratory. , 2002, Transplant infectious disease : an official journal of the Transplantation Society.
[193] J. Wingard,et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[194] D. Johnston,et al. Candida albicans stimulates local expression of leukocyte adhesion molecules and cytokines in vivo. , 2002, The Journal of infectious diseases.
[195] P. Ruutu,et al. Nosocomial bloodstream infections in Finnish hospitals during 1999-2000. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[196] E. Ghelardi,et al. Horizontal Transmission of Candida parapsilosis Candidemia in a Neonatal Intensive Care Unit , 2002, Journal of Clinical Microbiology.
[197] B. Wong,et al. Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections , 2002, Clinical Microbiology Reviews.
[198] E. Bow,et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.
[199] M. Buchanan-Chell,et al. Epidemiology, treatment and outcome of candidemia: a five‐year review at three Canadian hospitals , 2002, Mycoses.
[200] M. Netea,et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. , 2002, The Journal of infectious diseases.
[201] A. Bonnin,et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. , 2002, Journal of medical microbiology.
[202] B. D. de Pauw,et al. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients , 2002, British journal of haematology.
[203] M. Pfaller,et al. Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study , 2002, Journal of Clinical Microbiology.
[204] A. Colombo,et al. Risk Factors for Breakthrough Candidemia , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[205] A. Carrillo,et al. Comparison of Albicans ID2 agar plate with the germ tube for presumptive identification of Candida albicans. , 2002, Diagnostic microbiology and infectious disease.
[206] S. Sattar,et al. A quantitative study of the survival of two species of Candida on porous and non‐porous environmental surfaces and hands , 2002, Journal of applied microbiology.
[207] B. Rau,et al. Characteristics of Infection with Candida Species inPatients with Necrotizing Pancreatitis , 2002, World Journal of Surgery.
[208] E. Anaissie,et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.
[209] E. Anaissie,et al. Revisiting the source of candidemia: skin or gut? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[210] R. Poropatich,et al. Hospitalizations for fungal infections after renal transplantation in the United States , 2001, Transplant infectious disease : an official journal of the Transplantation Society.
[211] Yee-Chun Chen,et al. Molecular epidemiology of Candida colonizing critically ill patients in intensive care units. , 2001, Journal of the Formosan Medical Association = Taiwan yi zhi.
[212] L. Saiman,et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. , 2001, The Pediatric infectious disease journal.
[213] A. Schwarer,et al. Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy , 2001, Annals of Internal Medicine.
[214] M. Andreoni,et al. Two-year surveillance on fluconazole susceptibility of Candida spp isolates in a general and university hospital in Rome. , 2001, Diagnostic microbiology and infectious disease.
[215] M. Pfaller,et al. International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.
[216] G. Mejicano,et al. Vertebral osteomyelitis due to Candida species: case report and literature review. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[217] L. Saiman,et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[218] Gerald R. Fink,et al. The glyoxylate cycle is required for fungal virulence , 2001, Nature.
[219] M. Büchler,et al. Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. , 2001, Archives of surgery.
[220] R. Weinstein,et al. Prophylactic antifungal therapy in the intensive care unit. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[221] L. Mermel,et al. Guidelines for the Management of Intravascular Catheter-Related Infections , 2001, Infection Control & Hospital Epidemiology.
[222] M. Libman,et al. Prevalence and Antifungal Susceptibility of 442Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada , 2001, Journal of Clinical Microbiology.
[223] C. Kauffman,et al. Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[224] E. Bow,et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. , 2000, The Journal of antimicrobial chemotherapy.
[225] E. Anaissie,et al. A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia , 2000 .
[226] D. Kontoyiannis,et al. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. , 2000, Infectious disease clinics of North America.
[227] R. Jakesz,et al. Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality. , 2000, Shock.
[228] C. Kauffman,et al. Pathogenic Organisms Associated with Artificial Fingernails Worn by Healthcare Workers , 2000, Infection Control & Hospital Epidemiology.
[229] P. Grossi,et al. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. , 2000, Transplantation.
[230] J. Romero-Vivas,et al. The central nervous system and infection by Candida species. , 2000, Diagnostic microbiology and infectious disease.
[231] J. M. Peralta,et al. Strain Characterization of Candida parapsilosis Fungemia by Molecular Typing Methods , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[232] G Sherman,et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.
[233] D. Engelhard,et al. Fluconazole in transplant recipients: options and limitations , 2000, Transplant infectious disease : an official journal of the Transplantation Society.
[234] R. Margreiter,et al. Incidence of intraabdominal infection in a consecutive series of 40 enteric‐drained pancreas transplants with FK506 and MMF immunosuppression , 2000, Transplant international : official journal of the European Society for Organ Transplantation.
[235] Richard B. Johnston,et al. Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.
[236] D. Kajdasz,et al. Fluconazole Prophylaxis of Severe Candida Infection in Trauma and Postsurgical Patients: A Prospective, Double‐Blind, Randomized, Placebo‐Controlled Trial , 2000 .
[237] M. Klepser,et al. Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.
[238] M. Klepser,et al. Novel triazole antifungal agents , 2000, Expert opinion on investigational drugs.
[239] M. Territo,et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. , 2000, The American journal of medicine.
[240] R. Kandaswamy,et al. Decreased surgical risks of pancreas transplantation in the modern era. , 2000, Annals of surgery.
[241] L. Saiman,et al. Elucidating the Origins of Nosocomial Infections with Candida albicans by DNA Fingerprinting with the Complex Probe Ca3 , 1999, Journal of Clinical Microbiology.
[242] D. McClish,et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[243] J. Meis,et al. Nosocomial fungal infections: candidemia. , 1999, Diagnostic microbiology and infectious disease.
[244] G. Fadda,et al. Candidemia in HIV-Infected Subjects , 1999, European Journal of Clinical Microbiology and Infectious Diseases.
[245] L. Mele,et al. PCR-Restriction Enzyme Analysis for Detection ofCandida DNA in Blood from Febrile Patients with Hematological Malignancies , 1999, Journal of Clinical Microbiology.
[246] B. Lebeau,et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[247] R. Rennie,et al. Assessment of the Effect of Amphotericin B on the Vitality of Candida albicans , 1999, Antimicrobial Agents and Chemotherapy.
[248] M. Sarr,et al. Fungal infection in acute necrotizing pancreatitis. , 1999, Journal of the American College of Surgeons.
[249] L. Nicolle,et al. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[250] D. Sheehan,et al. Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.
[251] A. Hoerauf,et al. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. , 1998, Critical care medicine.
[252] L. Nicolle,et al. Invasive fungal infections in Canada from 1992 to 1994. , 1998, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.
[253] M. Ghannoum,et al. Mechanism of Fluconazole Resistance inCandida krusei , 1998, Antimicrobial Agents and Chemotherapy.
[254] M. Halpern,et al. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[255] S. Filler,et al. Secreted Aspartyl Proteinases and Interactions of Candida albicans with Human Endothelial Cells , 1998, Infection and Immunity.
[256] Yhu-Chering Huang,et al. Yeast carriage on hands of hospital personnel working in intensive care units. , 1998, The Journal of hospital infection.
[257] P. Robbins,et al. Cloning and Sequencing of a Candida albicans Catalase Gene and Effects of Disruption of This Gene , 1998, Infection and Immunity.
[258] R. Stratta. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation. , 1998, Transplantation proceedings.
[259] J. Sobel,et al. Nosocomial Candida glabrata Colonization: an Epidemiologic Study , 1998, Journal of Clinical Microbiology.
[260] F. Vermassen,et al. Management of candidal thrombophlebitis of the central veins: case report and review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[261] A. Scarcella,et al. Liposomal amphotericin B treatment for neonatal fungal infections. , 1998, The Pediatric infectious disease journal.
[262] R. Wenzel,et al. An outbreak of Candida parapsilosis prosthetic valve endocarditis. , 1997, Diagnostic microbiology and infectious disease.
[263] M. Ghannoum,et al. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei , 1997, Antimicrobial agents and chemotherapy.
[264] S. Chanock,et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis , 1997, Antimicrobial agents and chemotherapy.
[265] J. Karlowsky,et al. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. , 1997, Diagnostic microbiology and infectious disease.
[266] T. C. White,et al. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus , 1997, Antimicrobial agents and chemotherapy.
[267] M. Ghannoum,et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[268] E. Anaissie,et al. The epidemiology of hematogenous candidiasis caused by different Candida species. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[269] J. Ringers,et al. Infectious disease complications of simultaneous pancreas kidney transplantation. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[270] R. Rabinovici,et al. Candida pericarditis: clinical profile and treatment. , 1997, The Annals of thoracic surgery.
[271] M. Ghannoum,et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[272] M. Ghannoum,et al. Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans. , 1997, Microbiology.
[273] M. Arduino,et al. Candida parapsilosis bloodstream infections in neonatal intensive care unit patients: epidemiologic and laboratory confirmation of a common source outbreak. , 1996, The Pediatric infectious disease journal.
[274] D. Dunn,et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. , 1996, Journal of the American College of Surgeons.
[275] R. Gupta,et al. Invasive fungal infections in renal transplant recipients. , 1996, The Journal of infection.
[276] D. M. Lupan,et al. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans , 1996, Infection and immunity.
[277] K. Papadakis,et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. , 1996, The American journal of medicine.
[278] S. Kohno,et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia , 1996, Journal of clinical microbiology.
[279] S. Filler,et al. Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells , 1996, Infection and immunity.
[280] C. Viscoli,et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. , 1996, European journal of cancer.
[281] J. Perfect,et al. Fungal Infections in Lung and Heart‐Lung Transplant Recipients: Report of 9 Cases and Review of the Literature , 1996, Medicine.
[282] E. Anaissie,et al. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[283] N. Gow,et al. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance , 1996, Antimicrobial agents and chemotherapy.
[284] M. Pfaller,et al. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata , 1996, Journal of clinical microbiology.
[285] Deventer,et al. Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit , 1995, Journal of clinical microbiology.
[286] J. Swartz,et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility , 1995, Antimicrobial agents and chemotherapy.
[287] K. Kuchler,et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.
[288] D. Pittet,et al. Fungal infections in the critically ill , 1995 .
[289] M. Del Poeta,et al. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[290] S. Werner,et al. Nosocomial outbreak of Candida albicans sternal wound infections following cardiac surgery traced to a scrub nurse. , 1995, The Journal of infectious diseases.
[291] T. Parkinson,et al. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata , 1995, Antimicrobial agents and chemotherapy.
[292] D. Pittet,et al. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. , 1995, Archives of internal medicine.
[293] R. Wenzel. Nosocomial candidemia: risk factors and attributable mortality. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[294] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[295] M. Ghannoum,et al. Evidence implicating phospholipase as a virulence factor of Candida albicans , 1995, Infection and immunity.
[296] J. Shenep,et al. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[297] S. Filler,et al. Penetration and damage of endothelial cells by Candida albicans , 1995, Infection and immunity.
[298] S. Walmsley,et al. Use of fluconazole in the treatment of candidal endophthalmitis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[299] J. Pachón,et al. Prospective study of renal transplant infections in 50 consecutive patients , 1994, European Journal of Clinical Microbiology and Infectious Diseases.
[300] R. Auckenthaler,et al. Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.
[301] C. Girmenia,et al. Prospective study ofCandida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients , 1994, European Journal of Clinical Microbiology and Infectious Diseases.
[302] P. Bétrémieux,et al. Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit , 1994, The Pediatric infectious disease journal.
[303] A. Casadevall,et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole , 1994, Antimicrobial Agents and Chemotherapy.
[304] M. Pfaller,et al. High frequency of yeast carriage on hands of hospital personnel , 1994, Journal of clinical microbiology.
[305] M. Homma,et al. Strain relatedness of Candida albicans strains isolated from children with leukemia and their bedside parents , 1994, Journal of clinical microbiology.
[306] B. Doebbeling,et al. Investigation of the sequence of colonization and candidemia in nonneutropenic patients , 1994, Journal of clinical microbiology.
[307] L. Jacobs,et al. Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[308] F. Mandelli,et al. Fungemia in Patients with Leukemia , 1993, The American journal of the medical sciences.
[309] F. Stock,et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. , 1993, Diagnostic microbiology and infectious disease.
[310] J. Sobel,et al. Nosocomial acquisition of Candida albicans: an epidemiologic study. , 1993, The Journal of infectious diseases.
[311] J. Sobel,et al. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. , 1993, The American journal of medicine.
[312] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.
[313] R. Hector,et al. Compounds active against cell walls of medically important fungi , 1993, Clinical Microbiology Reviews.
[314] F. Odds,et al. Characterization of an azole-resistant Candida glabrata isolate , 1992, Antimicrobial Agents and Chemotherapy.
[315] R. Tosado-Acevedo,et al. Extraction and purification of a catalase from Candida albicans. , 1992, Puerto Rico Health Sciences Journal.
[316] K. Iwata. Drug resistance in human pathogenic fungi , 1992, European Journal of Epidemiology.
[317] J. L. Goodman,et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.
[318] M. Pfaller,et al. Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit. , 1992, The Journal of pediatrics.
[319] S. Filler,et al. Candida albicans adherence to endothelial cells. , 1992, Microvascular research.
[320] R. Dagan,et al. Pseudooutbreak of Candida guilliermondii fungemia in a neonatal intensive care unit , 1991, The Pediatric Infectious Disease Journal.
[321] R. Auckenthaler,et al. Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections. , 1991, The American journal of medicine.
[322] D. R. Weber,et al. Hepatosplenic candidiasis: successful treatment with fluconazole. , 1991, The American journal of medicine.
[323] E. Anaissie,et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. , 1991, The American journal of medicine.
[324] T J Walsh,et al. Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. , 1991, The New England journal of medicine.
[325] R. Wenzel,et al. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe , 1990, Journal of clinical microbiology.
[326] J. Dupouy-Camet,et al. Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis , 1990, Journal of clinical microbiology.
[327] David John Adams,et al. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. , 1990, The Biochemical journal.
[328] M. Pfaller,et al. Effects of cilofungin (LY121019) on carbohydrate and sterol composition ofCandida albicans , 1989, European Journal of Clinical Microbiology and Infectious Diseases.
[329] F. Mandelli,et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study , 1989, Cancer.
[330] R. Woolson,et al. Risk factors for hospital-acquired candidemia. A matched case-control study. , 1989, Archives of internal medicine.
[331] R F Woolson,et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.
[332] A. Gratwohl,et al. Bottled lemon juice--a cryptic source of invasive Candida infections in the immunocompromised host. , 1988, The Journal of infectious diseases.
[333] E. Larson,et al. Composition and density of microflora in the subungual space of the hand , 1988, Journal of clinical microbiology.
[334] J. O’Shea,et al. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. , 1986, Journal of immunology.
[335] G. Roberts,et al. Clinical evaluation of the lysis-centrifugation blood culture system for the detection of fungemia and comparison with a conventional biphasic broth blood culture system , 1984, Journal of clinical microbiology.
[336] P. Puccetti,et al. Phagocytic killing of Candida albicans by different murine effector cells. , 1983, Sabouraudia.
[337] W. Beggs. Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. , 1983, The Journal of antimicrobial chemotherapy.
[338] J. Solomkin,et al. Indications for therapy for fungemia in postoperative patients. , 1982, Archives of surgery.
[339] H. Malech,et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. , 1981, The American journal of medicine.
[340] D. Kerridge,et al. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study. , 1981, Sabouraudia.
[341] W. Merz,et al. Incidence of polyene-resistant yeasts recovered from clinical specimens , 1980, Antimicrobial Agents and Chemotherapy.
[342] A. Fauci,et al. Role of complement in host defense against experimental disseminated candidiasis. , 1978, The Journal of infectious diseases.
[343] J. E. Bennett,et al. Mode of action of 5-fluorocytosine. , 1978, Biochemical pharmacology.
[344] T. Sodeman,et al. Candida myocarditis without valvulitis. , 1976, The American journal of cardiology.
[345] R. Holz. THE EFFECTS OF THE POLYENE ANTIBIOTICS NYSTATIN AND AMPHOTERICIN B ON THIN LIPID MEMBRANES , 1974, Annals of the New York Academy of Sciences.
[346] B. de Kruijff,et al. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawii cells and lecithin liposomes. 3. Molecular structure of the polyene antibiotic-cholesterol complexes. , 1974, Biochimica et biophysica acta.
[347] J. Edwards,et al. OCULAR MANIFESTATIONS OF CANDIDA SEPTICEMIA: REVIEW OF SEVENTY-SIX CASES OF HEMATOGENOUS CANDIDA ENDOPHTHALMITIS , 1974, Medicine.
[348] R. Good,et al. Defective candidacidal capacity of polymorphonuclear leukocytes in chronic granulomatous disease of childhood. , 1969, The Journal of pediatrics.
[349] W. Krause,et al. Fungaemia and funguria after oral administration of Candida albicans. , 1969, Lancet.
[350] D. Louria,et al. Disseminated moniliasis In the Adult. , 1962 .
[351] A. Kumar. Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial , 2009 .
[352] M. Libman,et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[353] G. Ubeaud‐Séquier,et al. The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals , 2008, Clinical pharmacokinetics.
[354] G. Fätkenheuer,et al. Central venous catheter-related infections in hematology and oncology , 2008 .
[355] Steven D. Brown,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .
[356] J. Timsit,et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. , 2006, Chest.
[357] D. Andes,et al. Pharmacokinetics of antifungals : Implications for drug selection , 2006 .
[358] Y. Shan,et al. Early Presumptive Therapy with Fluconazole for Occult Candida Infection after Gastrointestinal Surgery , 2005, World Journal of Surgery.
[359] C. L. Gil,et al. Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: una visión multidisciplinar , 2005 .
[360] L. Letelier,et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. , 2005, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.
[361] J. W. Pickering,et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. , 2005, Journal of clinical microbiology.
[362] E. Estey,et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[363] M. Pfaller,et al. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[364] J. Decruyenaere,et al. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[365] D. Kovacevich,et al. Guidelines for the prevention of intravascular catheter-related infections: Centers for Disease Control and Prevention. , 2003, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
[366] J. Gavaldà,et al. [Guidelines for the treatment of infection due to Aspergillus spp]. , 2003, Enfermedades Infecciosas y Microbiologia Clinica.
[367] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[368] T. Calandra,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[369] S. Fanello,et al. Nosocomial Candida albicans acquisition in a geriatric unit: epidemiology and evidence for person-to-person transmission. , 2001, The Journal of hospital infection.
[370] E. Anaissie,et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[371] J. Sobel,et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[372] C. Kauffman,et al. Epidemiology of Yeast Colonization in the Intensive Care Unit , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[373] T. C. White,et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.
[374] R. Finberg,et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, The New England journal of medicine.
[375] P. Morel,et al. Kidney and pancreas transplantation: postoperative infectious complications. , 1999, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[376] E. Bow,et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[377] O. Lortholary,et al. Candidemia: a nosocomial complication in adults with late-stage AIDS. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[378] Hwei-Ling Peng,et al. Outbreak of Candida albicans fungaemia in a neonatal intensive care unit. , 1998, Scandinavian journal of infectious diseases.
[379] J. Serody,et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[380] S. Michaelis,et al. Sequence comparison of yeast ATP-binding cassette proteins. , 1995, Cold Spring Harbor symposia on quantitative biology.
[381] R. Bell,et al. Candida in pancreatic infection: a clinical experience. , 1994, The American surgeon.
[382] J. Savino,et al. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. , 1994, The Journal of trauma.
[383] A. Tunkel,et al. Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. , 1993, The American journal of medicine.
[384] A. Mason,et al. Fungal burn wound infection. A 10-year experience. , 1991, Archives of surgery.
[385] P. Jewesson,et al. Nonvalue of antigen detection immunoassays for diagnosis of candidemia. , 1990, Journal of clinical microbiology.
[386] F. Meunier. Empirical antifungal therapy in febrile granulocytopenic patients , 1989 .
[387] G. Talbot,et al. Persistent fever after recovery from granulocytopenia in acute leukemia. , 1988, Archives of internal medicine.
[388] T. Shawker,et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. , 1988, Annals of internal medicine.
[389] W. Whelan. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. , 1987, Critical reviews in microbiology.
[390] S. Lipton,et al. Candidal infection in the central nervous system. , 1984, American Journal of Medicine.
[391] F. Witebsky,et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.
[392] A. Polak,et al. Mode of action of 5-fluorocytosine and mechanisms of resistance. , 1975, Chemotherapy.
[393] J. Remington,et al. Disseminated candidiasis in the surgical patient. , 1972, Surgery.
[394] Martyn A. Frencha,et al. in patients: a systematic review and meta-analysis with a , 2022 .